Cyclohexylamine

Cyclohexylamine

SCHEMBL2347732

CCCCN.NC1CCCCC1

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.44
DNM1 Q05193 8/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ALDH1A1 P00352 1/20 0.42
TSHR P16473 1/20 0.42
EPHX1 P07099 1/20 0.42
SIGMAR1 Q99720 1/20 0.41
GNAI3 P08754 1/20 0.39
GNAO1 P09471 1/20 0.39
GNAI1 P63096 1/20 0.39
NAAA Q02083 1/20 0.36
DPP4 P27487 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cyclopentanamine SCHEMBL8188030 0.95 DNM1 (0.42) CYP1A2DNM1MEN1KMT2AALDH1A1
Cyclohexylamine SCHEMBL28135465 0.93 DNM1 (0.52) CYP1A2DNM1MEN1KMT2AALDH1A1
Dodecylamine SCHEMBL11756736 0.91 DNM1 (0.56) CYP1A2DNM1MEN1KMT2AALDH1A1
Cyclohexylamine SCHEMBL6657888 0.91 DNM1 (0.56) CYP1A2DNM1MEN1KMT2AALDH1A1
Cycloheptanamine SCHEMBL18263635 0.91 DNM1 (0.56) CYP1A2DNM1MEN1KMT2AALDH1A1
Cyclohexylamine SCHEMBL3138481 0.91 DNM1 (0.56) CYP1A2DNM1MEN1KMT2AALDH1A1
Cyclohexylamine SCHEMBL6865056 0.91 DNM1 (0.56) CYP1A2DNM1MEN1KMT2AALDH1A1
Decylamine SCHEMBL3259417 0.91 DNM1 (0.56) CYP1A2DNM1MEN1KMT2AALDH1A1
Cyclohexylamine SCHEMBL6865558 0.91 DNM1 (0.56) CYP1A2DNM1MEN1KMT2AALDH1A1
Octadecylamine SCHEMBL4528802 0.91 DNM1 (0.56) CYP1A2DNM1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110263854-A1 Improved Process For The Preparation Of Endothelin Receptor Antagonists MSN LABORATORIES LIMITED (IN) 2011-10-27 US claimed
EP-2350024-A2 IMPROVED PROCESS FOR THE PREPARATION OF ENDOTHELIN RECEPTOR ANTAGONISTS MSN Laboratories Limited (IN) 2011-08-03 EP claimed
WO-2010070658-A2 IMPROVED PROCESS FOR THE PREPARATION OF ENDOTHELIN RECEPTOR ANTAGONISTS MSN LABORATORIES LIMITED (IN) 2010-06-24 WO claimed
CN-106146416-A Nitrogen replaces 3 oxo 6 substituted-tetrahydro quinoxaline structural compounds, its preparation method and medical usage thereof 河南大学 2016-11-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263854-A1 Improved Process For The Preparation Of Endothelin Receptor Antagonists EDNRA, EDNRB, ECE1 CYP1A2 758/4885DNM1 1059/4885MEN1 1705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.